Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Pazopanib

Nature Reviews Drug Discovery volume 9, pages 17–18 (2010)Cite this article

Subjects

Abstract

 Pazopanib

In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Targeting growth factor signalling in renal cell carcinoma.

References

  1. Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).

    Article  PubMed  Google Scholar 

  2. Atkins, M. A. et al. Everolimus. Nature Rev. Drug Discov. 8, 535–536 (2009).

    Article  CAS  Google Scholar 

  3. Heng, D. Y. & Bukowski, R. M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676–682 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632–4640 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Kumar, R. et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012–2021 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Food and Drug Administration. FDA labelling information. FDA website [online], (2009).

  7. Sternberg, C. N. et al. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s A5021 (2009).

    Article  Google Scholar 

  8. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  9. Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524, (2006).

    Article  CAS  Google Scholar 

  10. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).

    Article  CAS  Google Scholar 

  11. IMS MIDAS (IMS Health, 2009).

  12. SG Cowen Research Team. SG Cowen Therapeutic Categories Outlook (Sep 2009).

  13. Hauber, A., Vosser, R. & Evans, D. JP Morgan Equity Research Report (11 Sep 2009).

Download references

Author information

Authors and Affiliations

  1. Ronald M. Bukowski is at Cleveland Clinic Taussig Cancer Cente, Cleveland, Ohio, USA. bukow464@sbcglobal.net,

    Ronald M. Bukowski

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R.M.B. has received honoraria and acted as a consultant for Pfizer, Novartis and Genentech, and has acted as a consultant for GSK and Bayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat Rev Drug Discov 9, 17–18 (2010). https://doi.org/10.1038/nrd3073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3073

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research